iNtODEWORLD | N-Rephasin SAL200 Phase 1b Multiple Ascending Dose (MAD) Study Initiation Meeting
17258
single,single-post,postid-17258,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

N-Rephasin SAL200 Phase 1b Multiple Ascending Dose (MAD) Study Initiation Meeting

iNtRON Biotechnology held SAL200’s Phase 1b MAD study initiation meeting at Seoul National University Hospital on January 16th, 2018.

Designated clinical research center, Seoul National University’s professors, doctors, nurses and other related participants to this study attended the meeting, and discussed detailed study process and plan on SAL200’s MAD study.

This MAD study for endolysin based biomedicine is the first trial in the world. Ongoing phase 2a study and the phase 1b study will proceed together, and we expect this progress in development will enhance successful global out-licensing possibilities.

it is iNtRON.



iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.